Kite Pharma, a California-based biotech focused on developing novel cancer immunotherapies, secured $20 million in its latest funding round. Kite has access to the National Cancer Institute's pipeline of engineered autologous peripheral blood T cells that can be targeted to multiple hematological and solid tumor types.

Full Story:

Related Summaries